ISRCTN12428408已完成3 期
Paxlovid in the treatment of COVID-19
Wenzhou Central Hospital0 个研究点目标入组 58 人开始时间: 2023年3月18日最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 58
研究概览
简要总结
2023 Results article in https://doi.org/10.3389/fmed.2023.1161193 (added 10/10/2023)
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Confirmation of COVID-19 infection within 24 h and positive nasopharyngeal swab for COVID-19 nucleic acid RNA
- •2. Age =12 years and weight =40 kg
- •3. Subjects of fertility must agree to use highly effective contraceptive methods
排除标准
- •1. Previous history of COVID-19 treatment
- •2. A known history of active liver disease
- •3. Patients on renal dialysis or have moderate to severe impaired renal function
- •4. The known human immunodeficiency virus (HIV) infection
- •5. Suspected or confirmed concurrent active systemic infections other than COVID-19 infection
- •6. Allergy or other contraindication to any component of the study intervention
- •7. Any drug or substance that is currently or expected to be used that is a high reliance on CYP3A4 enzyme clearance or strong CYP3A4 enzyme inducers
- •8. Pregnant or breastfeeding women
研究者
相似试验
招募中
不适用
Efficacy and Safety Evaluation of Paxlovid for COVID-19: a Real-world Case-control StudyCOVID-19 PneumoniaNCT05532852Ruijin Hospital728
招募中
不适用
A Real World Study of Paxlovid for the Treatment of Hospitalized Patients Confirmed With COVID-19COVID-19NCT05387369Huashan Hospital2,000
Unknown
早期 1 期
Paxlovid in the Treatment of COVID-19 Patients With UremiaCOVID-19UremiaNCT05386433Ruijin Hospital40
撤回
3 期
Proxalutamide Treatment for COVID-19 Patients in Intensive Care UnitCovid19SARS (Severe Acute Respiratory Syndrome)NCT04853927Applied Biology, Inc.
进行中（未招募）
3 期
PAxlovid loNg cOvid-19 pRevention triAl With recruitMent In the Community in NorwayPost COVID-19 Condition, UnspecifiedSARS-CoV2 InfectionCOVID-19NCT05852873Haukeland University Hospital2,000